Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
11 studies found for:    "congenital hyperinsulinism" OR "neonatal hyperinsulinism" OR "persistent hyperinsulinemic hypoglycemia" OR "familial hyperinsulinism"
Show Display Options
Rank Status Study
1 Recruiting Fluorodopa F 18 in Congenital Hyperinsulinism
Condition: Congenital Hyperinsulinism
Intervention: Drug: Fluorodopa F 18
2 Recruiting Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy
Condition: Congenital Hyperinsulinism
Intervention: Drug: Lanreotide autogel
3 Active, not recruiting Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Conditions: Congenital Hyperinsulinism;   Hyperinsulinism;   Persistent Hyperinsulinemic Hypoglycemia of Infancy;   CHI;   PHHI
Interventions: Drug: F-DOPA;   Radiation: PET scan
4 Active, not recruiting Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism
Condition: Congenital Hyperinsulinism
Intervention: Drug: exendin-(9-39)
5 Completed Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism
Condition: Non-focal Congenital Hyperinsulinism
Intervention: Procedure: restrictive pancreatic resection
6 Active, not recruiting Phase II Safety and Efficacy Study of F-DOPA PET/CT in Children With Hyperinsulinemic Hypoglycemia
Conditions: Congenital Hyperinsulinism (CHI);   Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Intervention: Drug: 18 F-DOPA
7 Recruiting Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
Condition: Congenital Hyperinsulinism
Interventions: Drug: Exendin-(9-39);   Drug: placebo
8 Recruiting Effect of Exendin-(9-39) On Glucose Requirements To Maintain Euglycemia
Condition: Congenital Hyperinsulinism
Intervention: Drug: Exendin-(9-39)
9 Completed Sandostatine® LP and Hyperinsulinism
Condition: Congenital Hyperinsulinism
Intervention: Drug: Sandostatine LP
10 Available 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
Conditions: Congenital Hyperinsulinism;   Beckwith-Wiedemann Syndrome;   Insulinoma
Intervention: Drug: 18F-DOPA
11 Not yet recruiting Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism
Condition: Conservatively Treated CHI Patients
Intervention:

Indicates status has not been verified in more than two years